BioPharma Dive December 7, 2021
Ned Pagliarulo

Gary Glick, a chemist and well-known biotech entrepreneur, has raised more than $200 million to launch the latest company aiming to harness advances in medicinal chemistry to invent new drugs for cancer and inflammatory diseases.

Called Odyssey Therapeutics, the startup is backed by OrbiMed Advisors, SR One Capital Management and half a dozen other venture capital firms that collectively staked Glick and his team with the sizable Series A financing round.

For now, Odyssey isn’t revealing much about the diseases or targets it hopes to go after, although its funding has allowed the company to sketch out seven drug discovery programs. The biotech’s goal, Glick said in an interview, is to advance between one and three drug candidates into clinical...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Investments, Pharma / Biotech, Trends
Gilead bets on Xilio cancer drug as biotech restructures
Pfizer shifts creative to Publicis in latest marketing move
Boundless Bio’s ‘BOLD’ IPO Reels In $100M for a New Kind of Cancer Drug
Joseph La Barge On The Challenges Of Advancing Gene Therapy, Finding The Right Support
Exact Sciences' posts positive data for its capsule-on-a-string test for esophageal cancer

Share This Article